Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Tafasitamab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Labeler NDC Package Code Non Proprietary Name Start Marketing Date End Marketing Date Category Code Dosage Form (Strength)
    26/09/2024 Boehringer Ingelheim GmbH
    Germany
    		 Boehringer Ingelheim Pharma GmbH and Co. KG 12714-219 Tafasitamab 2020-07-31 2025-12-31 DRUG FOR FURTHER PROCESSING POWDER (200mg/200mg)